No National Approach

Jan 08, 2021

As the US has no national SARS-CoV-2 genome sequencing program, it is unable to spot where in the country a recently identified viral strain may be circulating or keep an eye out for new, emerging viral variants, the New York Times writes.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Should Also Work

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

Worries About Increased Deadliness

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

Merck Stops SARS-CoV-2 Vaccine Development

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

PLOS Papers on Rare Venous Thromboembolism Variant, Vector Mosquito LncRNAs, More

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.

Menu